{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-000462","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2026-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.771183+00:00","generated_at":"2026-05-16T07:14:54.072216+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Teva posts FY 2025 revenue $17.3B (+4% YoY), non-GAAP EPS $2.93, guides FY26 rev $16.4-16.8B","bullets":["FY 2025 revenues $17.3B (+4% YoY); GAAP diluted EPS $1.21, non-GAAP diluted EPS $2.93.","Key innovative brands AUSTEDO ($2.26B, +34% YoY), AJOVY ($673M, +30%), UZEDY ($191M, +63%) drove 35% YoY growth.","Non-GAAP operating income margin 28.4% (vs 26.2% in 2024); free cash flow $2,396M.","Gross debt reduced to $16.8B, net debt to $13.3B; credit ratings upgraded by three agencies in 2025.","2026 outlook: revenues $16.4-16.8B, non-GAAP diluted EPS $2.57-2.77, free cash flow $2.0-2.4B."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-000462","json":"https://secwatch.observer/filing/0001171843-26-000462.json","markdown":"https://secwatch.observer/filing/0001171843-26-000462.md","text":"https://secwatch.observer/filing/0001171843-26-000462.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000117184326000462/0001171843-26-000462-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000117184326000462/f8k_012826.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T07:14:54.072216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}